

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

08/552,839  
attachment to  
Paper #14

\*\*\*\*\*  
FILE 'USPAT' ENTERED AT 12:40:59 ON 09 MAR 1999

\*\*\*\*\*  
\* WELCOME TO THE \*  
\* U. S. PATENT TEXT FILE \*  
\*\*\*\*\*

=> s adenovir? and vector?

4162 ADENOVIR?  
76009 VECTOR?  
L1 3331 ADENOVIR? AND VECTOR?

=> s l1 and early region 4

103206 EARLY  
438233 REGION  
2364327 4  
5 EARLY REGION 4  
(EARLY(W) REGION(W) 4)  
L2 5 L1 AND EARLY REGION 4

=> d 12,1-5,cit,ab

1. 5,851,806, Dec. 22, 1998, Complementary **adenoviral** systems and cell lines; Imre Kovesdi, et al., 435/91.41, 320.1, 325, 366; 536/24.2 [IMAGE AVAILABLE]

US PAT NO: 5,851,806 [IMAGE AVAILABLE] L2: 1 of 5

ABSTRACT:

The present invention provides multiply replication deficient **adenoviral vectors** having a spacer in at least one replication deficient **adenoviral** region, as well as complementing cell lines therefor. Also provided are means of constructing the multiply replication deficient **adenoviral vectors** and methods of use thereof, e.g., in gene therapy.

2. 5,837,511, Nov. 17, 1998, Non-group C **adenoviral vectors**; Erik S. Falck-Pedersen, et al., 435/6, 235.1, 320.1, 325, 456; 514/44 [IMAGE AVAILABLE]

US PAT NO: 5,837,511 [IMAGE AVAILABLE] L2: 2 of 5

ABSTRACT:

The present invention provides replication-deficient non-group C **adenoviral vectors**. Also provided is a therapeutic method, particularly relating to gene therapy, vaccination, and the like, involving the use of such **vectors** incorporating a foreign nucleic acid.

3. 5,670,488, Sep. 23, 1997, **Adenovirus vector** for gene therapy; Richard J. Gregory, et al., 514/44; 424/93.2; 435/320.1 [IMAGE AVAILABLE]

US PAT NO: 5,670,488 [IMAGE AVAILABLE] L2: 3 of 5

ABSTRACT:

Gene Therapy **vectors**, which are especially useful for cystic fibrosis, and methods using the **vectors** are disclosed

4. 5,639,661, Jun. 17, 1997, Genes and proteins for treating cystic fibrosis; Michael J. Welsh, et al., 435/252.3, 320.1; 536/23.5, 24.3 [IMAGE AVAILABLE]

US PAT NO: 5,639,661 [IMAGE AVAILABLE]

L2: 4 of 5

ABSTRACT:

Disclosed are genes encoding novel CF monomer proteins which have cystic fibrosis transmembrane conductance regulator (CFTR) protein function.

5. 5,616,326, Apr. 1, 1997, Recombinant canine **adenovirus** 2 (CAV-2); Norman Spibey, 424/199.1, 205.1, 207.1, 208.1, 224.1, 233.1, 818, 819; 435/235.1, 252.3, 320.1 [IMAGE AVAILABLE]

US PAT NO: 5,616,326 [IMAGE AVAILABLE]

L2: 5 of 5

ABSTRACT:

A non-essential region in strains of live non-pathogenic immunogenic canine **adenovirus** is described. The insertion of genes from pathogenic carnivora viruses into this region, with suitable expression control systems, without prejudicing the stable reproducibility of the **adenovirus vector** is described. Such recombinant canine **adenoviruses** modified to contain a gene coding for an antigen or immunogenic agent, in association with an effective promoter for the gene, are described.

=> d 1,3,fro

US PAT NO: 5,851,806 [IMAGE AVAILABLE]

L2: 1 of 5

DATE ISSUED: Dec. 22, 1998

TITLE: Complementary **adenoviral** systems and cell lines

INVENTOR: Imre Kovesdi, Rockville, MD  
Douglas E. Brough, Olney, MD  
Duncan L. McVey, Derwood, MD  
Joseph T. Bruder, Gaithersburg, MD  
Alena Lizonova, Rockville, MD

ASSIGNEE: GenVec, Inc., Rockville, MD (U.S. corp.)

APPL-NO: 08/572,126

DATE FILED: Dec. 14, 1995

REL-US-DATA: Continuation-in-part of Ser. No. 258,416, Jun. 10, 1994.

INT-CL: [6] C12P 19/34; C12N 15/11; C12N 5/16; C12N 5/22

US-CL-ISSUED: 435/91.41, 320.1, 325, 366; 536/24.2

US-CL-CURRENT: 435/91.41, 320.1, 325, 366; 536/24.2

SEARCH-FLD: 435/69.1, 91.1, 235.1, 246.1, 320.1, 91.41, 172.3, 325, 366; 536/23.1, 24.1, 24.2

REF-CITED:

U.S. PATENT DOCUMENTS

4,405,712	9/1983	Vande Woude	435/5
-----------	--------	-------------	-------

FOREIGN PATENT DOCUMENTS

94/68503	12/1994	Australia
94/72646	1/1995	Australia
2117668	9/1995	Canada
WO 94/28152	8/1994	France
2 707 664	1/1995	France
WO 94/08026	4/1994	World Intellectual Property Organization
WO 94/11506	5/1994	World Intellectual Property Organization
WO 94/12649	9/1994	World Intellectual Property Organization

PCT/US95/14793	11/1994	Organization World Intellectual Property Organization	424/78.08
WO 94/28938	12/1994	World Intellectual Property Organization	
WO 95/00655	1/1995	World Intellectual Property Organization	

#### OTHER PUBLICATIONS

- Brough et al., *Virology*, 190, 624-634 (1992).
- Fallaux et al., *Human Gene Therapy*, 7, 215-222 (1996).
- Graham et al., *J. Gen. Virol.*, 36, 59-72 (1977).
- Imler et al., *Gene Therapy*, 3, 75-84 (1996).
- Klessig et al., *Molecular and Cellular Biology*, 4(7), 1354-1362 (1984).
- Kreeger, *The Scientist*, 13, (Feb. 19, 1996).
- Krougliak et al., *Human Gene Therapy*, 6, 1575-1586 (1995).
- Schaack et al., *J. Virol.*, 4079-4085 (1995).
- Wang et al., *Gene Therapy*, 2, 775-783 (1995).
- Weinberg et al., *Proc. Natl. Acad. Sci.*, 80, 5383-86 (1983).
- Yeh et al., *J. Virol.*, 70(1), 559-565 (1996).
- Barr et al., "Efficient Catheter-Mediated Gene Transfer Into The Heart Using Replication-Defective Adenovirus," *Gene Therapy*, 1:51-58 (1994).
- Berkner et al., "Generation of Adenovirus By Transfection of Plasmids," *Nucleic Acids Research*, 1117:6003-6020 (1983).
- Boucher et al., "Gene Therapy For Cystic Fibrosis Using El-Deleted Adenovirus: A Phase I Trial In The Nasal Cavity," *Human Gene Therapy*, 5:615-639 (1994).
- Brough et al., "Construction, Characterization, and Utilization of Cell Lines Which Inducibly Express the Adenovirus DNA-Binding Protein," *Virology*, 190:624-634 (1992).
- Davidson et al., "Overproduction of Polyomavirus Middle T Antigen in Mammalian Cells Through the Use of an Adenovirus Vector," *Journal of Virology*, 61(4):1226-1239 (1987).
- Engelhardt et al., "Adenovirus-Mediated Transfer of the CFTR Gene to Lung of Nonhuman Primates: Biological Efficacy Study," *Humana Gene Therapy*, 4:759-769 (1993).
- Klessing et al., "Introduction, Stable Intergration, and Controlled Expression of a Chimeric Adenovirus Gene Whose Product Is Toxic to the Recipient Human Cell," *Molecular and Cellular Biology*, 4(7):1354-1362.
- Weinberg et al., "A Cell Line that Supports the Growth of a Defective Early Region 4 Deletion Mutant of Human Adenovirus Type 2," *Proc. Natl. Acad. Sci. USA*, 80:5383-5386 (1983).
- Yang et al., "Cellular Immunity to Viral Antigens Limits El-Deleted Adenoviruses for Gene Therapy," *Proc. Natl. Acad. Sci. USA*, 91:4407-4411 (1994).
- Armentano et al., "Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion," *Human Gene Therapy* 6:1343-1353 (1995).
- Berkner, "Development of Adenovirus Vectors for the Expression of Heterologous Genes," *BioTechniques*, vol. 6, No. 7, 616-629 (1988).
- Bout et al., "Lung Gene Therapy: In Vivo Adenovirus-Mediated Gene Transfer to Rhesus Monkey Airway Epithelium," *Human Gene Therapy* 5:3-10 (1994).
- Brough et al., "Multiple Functions of the Adenovirus DNA-Binding Protein Are Required for Efficient Viral DNA Synthesis," *Virology*, 196:269-281 (1993).
- Crystal et al., "Administration of an adenovirus containing the human cFTR cDNA to the respiratory tract of individuals with cystic fibrosis," *Nature Genetics*, vol. 8, (Sep. 1994).
- Gilardi et al., "Expression of human .alpha..sub.1 -antitrypsin using a recombinant adenovirus vector," *FEBS*, vol. 267, No. 1, 60-62 (Jul. 1990).
- Lemarchand et al., "Adenovirus-mediated transfer of a recombinant human .alpha..sub.1 -antitrypsin cDNA to human endothelial cells," *Proc. Natl. Acad. Sci. USA*, vol. 89, pp. 6482-6486, (Jul. 1992).
- Mastrangeli et al., "Diversity of Airway Epithelial Cell Targets for In Vivo Recombinant Adenovirus-mediated Gene Transfer," *The Journal of*

Clinical Investigation, Inc., vol. 91, 225-234 (Jan. 1993).  
Mittereder et al., "In Vivo Evaluation of the Safety of Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA to the Lung," Human Gene Therapy 5:731-744 (1994).  
Mittereder et al., "Evaluation of the Efficacy and Safety of In Vitro, Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA," Human Gene Therapy 5:717-729 (1994).  
Morin et al., "Nuclear Localization of the Adenovirus DNA-Binding Protein: Requirement for Two Signals and Complementmentation during Viral Infection," Molecular and Cellular Biology, pp. 4372-4380 (Oct. 1989).  
Rosenfeld et al., "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium," Cell, vol. 68, 143-155 (Jan. 10, 1992).  
Simon et al., "Adenovirus-Mediated Transfer of the CFTR Gene To Lung of Nonhuman Primates: Toxicity Study," Human Gene Therapy 4:771-780 (1993).  
Simon et al., "Adenovirus-Mediated Transfer of the CFTR Gene to Lung of Nonhuman Primates: Toxicity Study," Human Gene Therapy 4:771-780 (1993).  
Trapnell et al., "Gene therapy using adenoviral vectors," Current Opinion in Biotechnology, 5:617-625 (1994).  
Vos et al., "Charaterization of Adenovirus Type 5 Insertion and Deletion Mutants Encoding Altered DNA Binding Proteins," Virology 172:634-642 (1989).  
Yang et al., "Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis," Nature Genetics, vol. 7 pp. 362-369, (Jul. 1994).  
Cleghon et al., J. Virology, 63, 2289-2299 (1989).  
Rice et al., Virology, 156 (2), 366-376 (1987).  
Stuiver et al., J. Virology, 65:379-386 (1990).  
ART-UNIT: 185  
PRIM-EXMR: David Guzo  
ASST-EXMR: William Sandals  
LEGAL-REP: Leydig, Voit & Mayer, Ltd.

ABSTRACT:

The present invention provides multiply replication deficient **adenoviral vectors** having a spacer in at least one replication deficient **adenoviral** region, as well as complementing cell lines therefor. Also provided are means of constructing the multiply replication deficient **adenoviral vectors** and methods of use thereof, e.g., in gene therapy.

63 Claims, 21 Drawing Figures

US PAT NO: 5,670,488 [IMAGE AVAILABLE] L2: 3 of 5  
DATE ISSUED: Sep. 23, 1997  
TITLE: **Adenovirus vector** for gene therapy  
INVENTOR: Richard J. Gregory, Carlsbad, CA  
Donna Armentano, Watertown, MA  
Larry A. Couture, Framingham, MA  
Alan E. Smith, Wellesley, MA  
ASSIGNEE: Genzyme Corporation, Framingham, MA (U.S. corp.)  
APPL-NO: 08/136,742  
DATE FILED: Oct. 13, 1993  
REL-US-DATA: Continuation-in-part of Ser. No. 985,478, Dec. 3, 1992, abandoned.  
INT-CL: [6] A61K 48/00; C12N 15/00  
US-CL-ISSUED: 514/44; 424/93.2; 435/320.1; 935/62  
US-CL-CURRENT: 514/44; 424/93.2; 435/320.1  
SEARCH-FLD: 435/320.1; 514/44; 424/93.2; 935/62  
REF-CITED:

U.S. PATENT DOCUMENTS

4,920,209 4/1990 Davis

# FOREIGN PATENT DOCUMENTS

0 185 573	6/1986	European Patent Office
0 446 017	9/1990	European Patent Office
WO 91/02796	8/1990	World Intellectual Property Organization
WO 93/12240	12/1992	World Intellectual Property Organization
WO 93/12756	12/1992	World Intellectual Property Organization
WO 91/10734	12/1992	World Intellectual Property Organization
93 19191	9/1993	World Intellectual Property Organization

## OTHER PUBLICATIONS

- Zabner, J. et al. (1993) "Adenovirus-Mediated Gene Transfer Transiently Corrects the Chloride Transport Defect in Nasal Epithelia of Patients with Cystic Fibrosis" *Cell* 75:207-216.
- Rosenfeld, M.A. et al. (1992) "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium" *Cell* 68: 143-155.
- Sassone-Corsi, P. et al. (1983) "Far upstream sequences are required for efficient transcription from the adenovirus-2 E1A transcription unit" *Nucleic Acid Research* 11:8735-8745.
- Yoshimura, K. et al. (1993) "Adenovirus-mediated Augmentation of Cell Transfection with Unmodified Plasmid Vectors" *J. Biol. Chem.* 268(4):2300-2303.
- Engelhardt, J.F. et al. (1993) "Direct Gene Transfer of Human CFTR into Human Bronchial Epithelia of Xenografts with E1-deleted Adenovirus" *Nat. Gen.* 4:27-34.
- Flotte, T.R. et al. (1993) "Expression of the Cystic Fibrosis Transmembrane Conductance Regulator from a Novel Adeno-associated Virus Promoter" *J. Biol. Chem.* 268(5):3781-3790.
- Johnson, L.G. et al. (1992) "Efficiency of Gene Transfer for Restoration of Normal Airway Epithelial Function in Cystic Fibrosis" *Nat. Gen.* 2:21-25.
- Welsh, M.J. and Smith, A.E. (1993) "Molecular Mechanisms of CFTR Chloride Channel Dysfunction in Cystic Fibrosis" *Cell* 73:1251-1254.
- Hyde, S.C. et al. (1993) "Correction of the Ion Transport Defect in Cystic Fibrosis Transgenic Mice by Gene Therapy" *Nature* 362:250-255.
- Smith, A.E. (1992) "Emerging Therapies for Cystic Fibrosis" *Section V-Topics in Biology in Ann. Rep. Med. Chem.* 27:235-243.
- Yoshimura, K. et al. (1992) "Expression of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene in the Mouse Lung after in Vivo Intratracheal Plasmid-Mediated Gene Transfer" *Nucleic Acids Res.* 20(12):3233-3240.
- Rosenfeld, M.A. et al. (1991) "Adenovirus-Mediated Transfer of a Recombinant .alpha.-1-Antitrypsin Gene to the Lung Epithelium in Vivo" *Science* 252:431-434.
- Rosenfeld, M.A. et al. (1991) "In Vivo Transfer of the Human Cystic Fibrosis Gene to the Respiratory Epithelium" *Clin. Res.* 39(2):311A.
- Anderson, M.P. et al. (1991) "Generation of cAMP-Activated Chloride Currents by Expression of CFTR" *Science* 251:679-682.
- Kartner, N. et al. (1991) "Expression of the Cystic Fibrosis Gene in Non-Epithelial Invertebrate Cells Produces a Regulated Anion Conductance" *Cell* 64:681-691.
- Anderson, M.P. et al. (1991) "Demonstration That CFTR Is a Chloride Channel by Alteration of Its Anion Selectivity" *Science* 253:202-205.
- Tabcharani, J.A. et al. (1991) "Phosphorylation-Regulated Cl-Channel in CHO Cells Stably Expressing the Cystic Fibrosis Gene" *Nature* 352:628-631.
- Rich, D.P. et al. (1991) "Effect of Deleting the R Domain on CFTR-Generated Chloride Channels" *Science* 253:205-207.
- Berger, H.A. et al. (1991) "Identification and Regulation of the Cystic

Fibrosis Transmembrane Conductance Regulator-Generated Chloride Channel" J. Clin. Invest. 88:1422-1431.

Drumm, M.L. et al. (1990) "Correction of the Cystic Fibrosis Defect In Vitro By Retrovirus-Mediated Gene Transfer" Cell 1227-1233.

Gregory, R.J. et al. (1990) "Expression and Characterization of the Cystic Fibrosis Transmembrane Conductance Regulator" Nature 347:382-386.

Rich, D.P. et al. (1990) "Expression of the Cystic Fibrosis Transmembrane Conductance Regulator Corrects Defective Chloride Channel Regulation in Cystic Fibrosis Airway Epithelial Cells" Nature 347:358-363.

Huang, M.T.F. et al. (1990) "Intervening Sequences Increase Efficiency of RNA 3'Processing and Accumulation of Cytoplasmic RNA" Nucleic Acids Res. 18(4):937-947.

Riordan, J.R. et al. (1989) "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA" Science 245:1066-1073.

Rommens, J.H. et al. (1989) "Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping" Science 245: 1059-1065.

Kerem, B.S. et al. (1989) "Identification of the Cystic Fibrosis Gene: Genetic Analysis" Science 245:1073-1080.

Berker (1988) Biotechniques 6, 616-627.

ART-UNIT: 189

PRIM-EXMR: Deborah Crouch

LEGAL-REP: Brumbaugh, Graves Donohue & Raymond

ABSTRACT:

Gene Therapy **vectors**, which are especially useful for cystic fibrosis, and methods for using the **vectors** are disclosed.

19 Claims, 67 Drawing Figures

=> d 1,3,clms

US PAT NO: 5,851,806 [IMAGE AVAILABLE]

L2: 1 of 5

CLAIMS:

CLMS(1)

What is claimed is:

1. An **adenoviral vector** comprising (a) an **adenoviral** genome deficient in the E4 region of the **adenoviral** genome,, (b) a spacer of at least 15 base pairs in the E4 region of the **adenoviral** genome, and (c) a passenger gene, wherein said spacer comprises a sequence that is non-native to the E4 region of the **adenoviral** genome, and wherein the viral production level of said **adenoviral vector** is greater than the viral production level of said **adenoviral vector** without said spacer.

CLMS(2)

2. The **adenoviral vector** of claim 1, wherein the viral production level of said **adenoviral vector** without said spacer and without said passenger gene is lower than the viral production level of said **adenoviral vector** without said spacer, said passenger gene, and said deficiency in the E4 region of the **adenoviral** genome.

CLMS(3)

3. A host cell comprising the **adenoviral vector** of claim 1.

CLMS(4)

4. A composition comprising the **adenoviral vector** of claim 1,

and a carrier therefor

CLMS(5)

5. A replication competent **adenovirus**-free stock of the **adenoviral vector** of claim 1, wherein said spacer comprises said passenger gene, wherein said **adenoviral vector** is prepared in a cell line which will support the growth of said **adenoviral vector**, and wherein the genome of said cell line is free of overlapping sequences with said **adenoviral vector** such that said cell genome will not mediate a recombination event which would produce a replication competent **adenoviral vector**.

CLMS(6)

6. A method of genetically modifying a cell in vitro, which comprises contacting said cell with the **adenoviral vector** of claim 1.

CLMS(7)

7. The **adenoviral vector** of claim 1, wherein said **adenoviral** genome is deficient in one or more essential gene functions of the E4 region of the **adenoviral** genome.

CLMS(8)

8. The **adenoviral vector** of claim 7, wherein said **adenoviral** genome is deficient in one or more essential gene functions of another region of the **adenoviral** genome.

CLMS(9)

9. The **adenoviral vector** of claim 8, wherein said another region is the E1 region of the **adenoviral** genome.

CLMS(10)

10. The **adenoviral vector** of claim 1, wherein said **adenoviral** genome is deleted of the E4 region of the **adenoviral** genome.

CLMS(11)

11. The **adenoviral vector** of claim 10, wherein said **adenoviral** genome is deficient in one or more other essential gene functions of another region of the **adenoviral** genome.

CLMS(12)

12. The **adenoviral vector** of claim 1, wherein said **adenoviral** genome is deleted of the E4 region of the **adenoviral** genome except the E4 promoter and the E4 polyadenylation sequence.

CLMS(13)

13. The **adenoviral vector** of claim 12, wherein said **adenoviral** genome is deficient in one or more other essential gene functions of another region of the **adenoviral** genome.

CLMS(14)

14. The **adenoviral vector** of claim 1, wherein said **adenoviral** genome is deleted of the E4 region of the **adenoviral** genome except the E4 polyadenylation sequence.



CLMS (15)

15. The **adenoviral vector** of claim 14, wherein said **adenoviral** genome is deficient in one or more essential gene functions of another region of the **adenoviral** genome.

CLMS (16)

16. The **adenoviral vector** of claim 1, wherein said **adenoviral** genome is further deficient in the E2A region of the **adenoviral** genome.

CLMS (17)

17. The **adenoviral vector** of claim 16, wherein said E2A region comprises a portion of the **adenoviral** genome which encodes amino acids of the Nt domain of the DBP sufficient to allow for viral production, and wherein said E2A region is deficient in the portion of the **adenoviral** genome which encodes amino acid sequences of the Ct domain that are necessary for DNA binding.

CLMS (18)

18. The **adenoviral vector** of claim 1, wherein said spacer is about 100 to about 12,000 base pairs.

CLMS (19)

19. A method of genetically modifying a cell in vitro, which comprises contacting said cell with the **adenoviral vector** of claim 18.

CLMS (20)

20. The **adenoviral vector** of claim 18, wherein said spacer is about 500 to about 8,000 base pairs.

CLMS (21)

21. The **adenoviral vector** of claim 20, wherein said spacer is about 1,500 to about 6,000 base pairs.

CLMS (22)

22. The **adenoviral vector** of claim 1, wherein said spacer comprises a polyadenylation sequence other than an E4 **adenoviral** polyadenylation sequence.

CLMS (23)

23. The **adenoviral vector** of claim 22, wherein said spacer comprises an SV40 polyadenylation sequence.

CLMS (24)

24. A method of genetically modifying a cell in vitro, which comprises contacting said cell with the **adenoviral vector** of claim 22.

CLMS (25)

25. A replication competent **adenovirus-free** stock of the **adenoviral vector** of any of claims 1, 2 and 7-17, wherein said spacer comprises a polyadenylation sequence other than an E4 **adenoviral** polyadenylation sequence.

CLMS (26)

26. The replication competent **adenovirus**-free stock of claim 25, wherein said spacer comprises an SV40 polyadenylation sequence.

CLMS (27)

27. A replication competent **adenovirus**-free stock of the **adenoviral vector** of claim 1, wherein said spacer comprises a polyadenylation sequence other than an E4 **adenoviral** polyadenylation sequence, wherein said **adenoviral vector** is prepared in a cell line which will support the growth of said **adenoviral vector**, and wherein the genome of said cell line is free of overlapping sequences with said **adenoviral vector** such that said cell genome will not mediate a recombination event which would produce a replication competent **adenoviral vector**.

CLMS (28)

28. The replication competent **adenovirus**-free stock of claim 27, wherein said spacer comprises an SV40 polyadenylation sequence.

CLMS (29)

29. A replication competent **adenovirus**-free stock of the **adenoviral vector** of any of claims 1, 2 and 7-17, wherein said spacer comprises a polyadenylation sequence other than an E4 **adenoviral** polyadenylation sequence, wherein said **adenoviral vector** is prepared in a cell line which will support the growth of said **adenoviral vector**.

CLMS (30)

30. The replication competent **adenovirus**-free stock of claim 29, wherein said spacer comprises an SV40 polyadenylation sequence.

CLMS (31)

31. A replication competent **adenovirus**-free stock of the **adenoviral vector** of any of claims 1, 2 and 7-17, wherein said spacer comprises said passenger gene, wherein said **adenoviral vector** is prepared in a cell line which will support the growth of said **adenoviral vector**.

CLMS (32)

32. A method of increasing the propagation in a complementing cell line of an **adenoviral vector** comprising (a) an **adenoviral** genome deficient in the E4 region and (b) a passenger gene, which method comprises incorporating into the E4 region of the **adenoviral** genome of said **adenoviral vector** a spacer comprising at least about 15 base pairs, wherein said spacer comprises a sequence that is non-native to the E4 region of the **adenoviral** genome, thereby resulting in an increase in the viral production level of said **adenoviral vector**.

CLMS (33)

33. The method of claim 32, wherein said **adenoviral** genome is deficient in one or more essential gene functions of another region of the **adenoviral** genome.

CLMS (34)

34. The method of claim 32, wherein said **adenoviral** genome is deficient in one or more essential gene functions of the E4 region of the

**adenoviral** genome.

CLMS (35)

35. The method of claim 34, wherein said **adenoviral** genome is deficient in one or more essential gene functions of another region of the **adenoviral** genome.

CLMS (36)

36. The method of claim 34, wherein said **adenoviral** genome is further deficient in at least one or more essential gene functions of the E1 region of the **adenoviral** genome.

CLMS (37)

37. The method of claim 32, wherein said **adenoviral** genome is deleted of all the open reading frames of the E4 region of the **adenoviral** genome.

CLMS (38)

38. The method of claim 37, wherein said **adenoviral** genome is deficient in one or more essential gene functions of another region of the **adenoviral** genome.

CLMS (39)

39. The method of claim 32, wherein said **adenoviral** genome is deleted of the E4 region of the **adenoviral** genome except the E4 promoter and the E4 polyadenylation sequence.

CLMS (40)

40. The method of claim 39, wherein said **adenoviral** genome is deficient in one or more essential gene functions of another region of the **adenoviral** genome.

CLMS (41)

41. The method of claim 39, wherein said **adenoviral** genome is deleted of the E4 region of the **adenoviral** genome except the E4 polyadenylation sequence.

CLMS (42)

42. The method of claim 32, wherein said spacer is about 100 to about 12,000 base pairs.

CLMS (43)

43. The method of claim 42, wherein said spacer is about 500 to about 8,000 base pairs.

CLMS (44)

44. The method of claim 42, wherein said spacer is about 1,500 to about 6,000 base pairs.

CLMS (45)

45. The method of claim 32, wherein said spacer comprises a polyadenylation sequence other than an E4 **adenoviral** polyadenylation sequence.

CLMS (46)

46. The method of claim 45, wherein said spacer comprises an SV40 polyadenylation sequence.

CLMS (47)

47. An **adenoviral vector** comprising a portion of the E2A region of the **adenoviral** genome which encodes amino acids of the Nt domain of the DBP sufficient to allow for viral production, and wherein said E2A region is deficient in the portion of the **adenoviral** genome which encodes amino acid sequences of the Ct domain that are necessary for DNA bindings and further wherein the **adenoviral vector** comprises a passenger gene.

CLMS (48)

48. The **adenoviral vector** of claim 47, wherein said **adenoviral** genome is deficient in one or more essential gene functions of another region of the **adenoviral** genome.

CLMS (49)

49. An **adenoviral vector** comprising (a) an **adenoviral** genome deficient in the E4 region of the **adenoviral** genome, and (b) a spacer of at least 15 base pairs in the E4 region of the **adenoviral** genome, wherein said spacer comprises a passenger gene that is non-native to the E4 region of the **adenoviral** genome, and wherein the viral production level of said **adenoviral vector** is greater than the viral production level of said **adenoviral vector** without said spacer.

CLMS (50)

50. The **adenoviral vector** of claim 49, wherein said **adenoviral** genome is deficient in one or more essential gene functions of the E4 region of the **adenoviral** genome.

CLMS (51)

51. The **adenoviral vector** of claim 49, wherein the viral production level of said **adenoviral vector** without said spacer and without said passenger gene is lower than the viral production level of said **adenoviral vector** without said spacer, said passenger gene, and said deficiency in the E4 region of the **adenoviral** genome.

CLMS (52)

52. The **adenoviral vector** of claim 50, wherein said **adenoviral** genome is deficient in one or more essential gene functions of another region of the **adenoviral** genome.

CLMS (53)

53. The **adenoviral vector** of claim 52, wherein said another region is the E1 region of the **adenoviral** genome.

CLMS (54)

54. The **adenoviral vector** of claim 52, wherein said **adenoviral** genome is deleted of the E4 region of the **adenoviral** genome.

CLMS (55)

55. The **adenoviral vector** of claim 54, wherein said

**adenoviral** genome is deficient in one or more other essential gene functions of another region of the **adenoviral** genome.

CLMS (56)

56. The **adenoviral vector** of claim 52, wherein said **adenoviral** genome is deleted of the E4 region of the **adenoviral** genome except the E4 promoter and the E4 polyadenylation sequence.

CLMS (57)

57. The **adenoviral vector** of claim 56, wherein said **adenoviral** genome is deficient in one or more other essential gene functions of another region of the **adenoviral** genome.

CLMS (58)

58. The **adenoviral vector** of claim 49, wherein said **adenoviral** genome is deleted of the E4 region of the **adenoviral** genome except the E4 polyadenylation sequence.

CLMS (59)

59. The **adenoviral vector** of claim 50, wherein said **adenoviral** genome is deficient in one or more essential gene functions of another region of the **adenoviral** genome.

CLMS (60)

60. The **adenoviral vector** of claim 49, wherein said **adenoviral** genome is further deficient in the E2A region of the **adenoviral** genome.

CLMS (61)

61. The **adenoviral vector** of claim 60, wherein said E2A region comprises a portion of the **adenoviral** genome which encodes amino acids of the Nt domain of the DBP sufficient to allow for viral production, and wherein said E2A region is deficient in the portion of the **adenoviral** genome which encodes amino acid sequences of the Ct domain that are necessary for DNA binding.

CLMS (62)

62. A replication competent **adenovirus-free** stock of the **adenoviral vector** of any of claims 49-61.

CLMS (63)

63. A method of increasing the propagation in a complementing cell line of an **adenoviral vector** comprising an **adenoviral** genome deficient in the E4 region, which method comprises incorporating into the E4 region of the **adenoviral** genome of said **adenoviral vector** a spacer comprising at least about 15 base pairs, wherein said spacer comprises a passenger gene that is non-native to the E4 region of the **adenoviral** genome, thereby resulting in an increase in the viral production level of said **adenoviral vector**.

US PAT NO: 5,670,488 [IMAGE AVAILABLE]

L2: 3 of 5

CLAIMS:

CLMS (1)

We claim:

1. An **adenoviral vector** comprising an **adenovirus** genome from which one or more of the E4 open reading frames has been deleted, but retaining sufficient E4 sequences to promote virus replication in vitro, and additionally comprising a DNA sequence of interest operably linked to expression control sequences and inserted into said **adenoviral** genome.

CLMS(2)

2. The **vector** of claim 1 wherein a PGK promoter is operably linked to the DNA sequence of interest.

CLMS(3)

3. The **vector** of claim 1 from which the Ela and Elb regions of the **adenovirus** genome have been deleted.

CLMS(4)

4. The **vector** of claim 1 from which the E3 region of the **adenovirus** genome has been deleted.

CLMS(5)

5. The **adenoviral vector** of claim 1 in which open reading frame 6 of the E4 region is retained in the **adenovirus** genome.

CLMS(6)

6. The **adenoviral vector** of claim 1 in which open reading frame 3 of the E4 region is retained in the **adenovirus** genome.

CLMS(7)

7. The **adenoviral vector** of claim 1 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.

CLMS(8)

8. The **adenoviral vector** of claim 2 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.

CLMS(9)

9. The **adenoviral vector** of claim 3 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.

CLMS(10)

10. The **adenoviral vector** of claim 3 wherein the DNA sequence is inserted into the deleted Ela and Elb regions of the **adenoviral** genome.

CLMS(11)

11. The **adenoviral vector** of claim 5 wherein the DNA sequence encodes cystic fibrosis transmembrane regulator protein.

CLMS(12)

12. The **adenoviral vector** of claim 6 wherein a cytomegalovirus promoter is operably linked to the DNA sequence of interest.

CLMS(13)

13. A method for providing cystic fibrosis transmembrane conductance regulator protein to airway epithelial cells of a cystic fibrosis patient comprising administering directly to airway epithelial cells of the patient an **adenoviral vector**, said **vector** comprising an **adenovirus** genome from which one or more E4 open reading frames has been deleted, but retaining sufficient E4 sequences to promote virus replication in vitro, and additionally comprising a DNA sequence encoding cystic fibrosis transmembrane regulator protein operably linked to expression control sequences and inserted into the E1 region said **adenoviral** genome, under conditions whereby the DNA sequence encoding cystic fibrosis transmembrane regulator protein is expressed and a functional chloride ion channel is produced in the airway epithelial cells of the patient.

CLMS (14)

14. The method of claim 13 wherein open reading frame 6 of the E4 region of the **adenovirus** genome is retained in the **vector**.

CLMS (15)

15. The method of claim 13 wherein the expression control sequences operably linked to the DNA sequence comprise the PGK promoter.

CLMS (16)

16. The method of claim 13 in which the Ela and Elb regions of the **adenovirus** genome of the **vector** have been deleted.

CLMS (17)

17. The method of claim 13 in which the E3 region of the **adenovirus** genome of the **vector** has been deleted.

CLMS (18)

18. The method of claim 13 wherein open reading frame 3 of the E4 region of the **adenovirus** genome is retained in the **vector**.

CLMS (19)

19. The method of claim 18 wherein the expression control sequences operably linked to the DNA sequence comprise a cytomegalovirus promoter.